These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29948022)

  • 1. Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients.
    Le Saux O; Bourmaud A; Rioufol C; Colomban O; Guitton J; Schwiertz V; Regnier V; You B; Ranchon F; Maraval-Gaget R; Girard P; Chauvin F; Freyer G; Tod M; Henin E; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):319-327. PubMed ID: 29948022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to oral anticancer chemotherapy: What influences patients' over or non-adherence? Analysis of the OCTO study through quantitative-qualitative methods.
    Bourmaud A; Henin E; Tinquaut F; Regnier V; Hamant C; Colomban O; You B; Ranchon F; Guitton J; Girard P; Freyer G; Tod M; Rioufol C; Trillet-Lenoir V; Chauvin F
    BMC Res Notes; 2015 Jul; 8():291. PubMed ID: 26142140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Validation of a questionnaire assessing patients' adherence and skill level of management for oral capecitabine treatment].
    Baudot A; Oriol M; Tinquaut F; Moine V; Moriceau G; Muron T; Pacaut C; Collard O; Jacquin JP; Saban-Roche L; Bosacki C; Regnier-Denois V; Chauvin F; Bourmaud A
    Bull Cancer; 2016 Mar; 103(3):241-51. PubMed ID: 26917467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.
    Partridge AH; Archer L; Kornblith AB; Gralow J; Grenier D; Perez E; Wolff AC; Wang X; Kastrissios H; Berry D; Hudis C; Winer E; Muss H
    J Clin Oncol; 2010 May; 28(14):2418-22. PubMed ID: 20368559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
    O'Donnell PH; Trubetskoy V; Nurhussein-Patterson A; Hall JP; Nath A; Huo D; Fleming GF; Ingle JN; Abramson VG; Morrow PK; Storniolo AM; Forero A; Van Poznak C; Liu MC; Chang JC; Merkel DE; Peppercorn JM; Rugo HS; Dees EC; Hahn OM; Hoffman PC; Rosner GL; Huang RS; Ratain MJ; Cox N; Olopade OI; Wolff AC; Dolan ME; Nanda R;
    Breast Cancer Res Treat; 2020 Jun; 181(3):623-633. PubMed ID: 32378051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study on adherence to capecitabine among patients with colorectal cancer and metastatic breast cancer.
    Figueiredo Junior AG; Forones NM
    Arq Gastroenterol; 2014; 51(3):186-91. PubMed ID: 25296077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.
    Simons S; Ringsdorf S; Braun M; Mey UJ; Schwindt PF; Ko YD; Schmidt-Wolf I; Kuhn W; Jaehde U
    Support Care Cancer; 2011 Jul; 19(7):1009-18. PubMed ID: 20552377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features of oral chemotherapy: results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK.
    Brearley SG; Craven O; Saunders M; Swindell R; Molassiotis A
    Eur J Cancer Care (Engl); 2010 Jul; 19(4):425-33. PubMed ID: 19708942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine non-adherence: exploration of magnitude, nature and contributing factors.
    Bhattacharya D; Easthall C; Willoughby KA; Small M; Watson S
    J Oncol Pharm Pract; 2012 Sep; 18(3):333-42. PubMed ID: 22298660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing adherence to oral chemotherapy using different measurement methods: Lessons learned from capecitabine.
    Walter T; Wang L; Chuk K; Ng P; Tannock IF; Krzyzanowska MK
    J Oncol Pharm Pract; 2014 Aug; 20(4):249-56. PubMed ID: 24022406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
    Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
    Gieschke R; Burger HU; Reigner B; Blesch KS; Steimer JL
    Br J Clin Pharmacol; 2003 Mar; 55(3):252-63. PubMed ID: 12630975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis.
    Nishijima TF; Suzuki M; Muss HB
    Breast Cancer Res Treat; 2016 Apr; 156(2):227-36. PubMed ID: 26988358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.
    Lou Y; Wang Q; Zheng J; Hu H; Liu L; Hong D; Zeng S
    Chem Res Toxicol; 2016 Oct; 29(10):1591-1601. PubMed ID: 27631426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous, low-dose capecitabine for patients with recurrent colorectal cancer.
    Romiti A; Onesti CE; Roberto M; Barucca V; Tomao S; D'Antonio C; Durante V; Milano A; Falcone R; Di Rocco R; Righini R; Marchetti P
    Med Oncol; 2015 Mar; 32(3):54. PubMed ID: 25638466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse reactions and adherence to capecitabine: A prospective study in patients with gastrointestinal cancer.
    Visacri MB; Duarte NC; Lima TM; de Souza RN; Cobaxo TS; Teixeira JC; Barbosa CR; Dias LP; Tavares MG; Pincinato EC; Lima CS; Moriel P
    J Oncol Pharm Pract; 2022 Mar; 28(2):326-336. PubMed ID: 33470162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Telephone-Based Follow-Up on Adherence, Efficacy, and Toxicity of Oral Capecitabine-Based Chemotherapy.
    Eldeib HK; Abbassi MM; Hussein MM; Salem SE; Sabry NA
    Telemed J E Health; 2019 Jun; 25(6):462-470. PubMed ID: 30048216
    [No Abstract]   [Full Text] [Related]  

  • 19. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
    Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
    J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence and safety study in patients on treatment with capecitabine.
    Fernández-Ribeiro F; Olivera-Fernández R; Crespo-Diz C
    Farm Hosp; 2017 Mar; 41(2):204-221. PubMed ID: 28236798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.